喘息性支气管炎经孟鲁司特钠治疗临床疗效观察  

Clinical Observation on Montelukast in the Treatment of Asthmatic Bronchitis

作　　者：来静[1,2] 杨琳[1] 

机构地区：[1]西安交通大学第二附属医院儿科,陕西西安710004 [2]陕西省安康市中心医院儿科,陕西安康710004

出　　处：《中国继续医学教育》2017年第15期163-165,共3页China Continuing Medical Education

摘　　要：目的分析小儿支气管炎(喘息性)经孟鲁司特钠治疗临床疗效观察及对机体气道高反应性的预防作用。方法选取我院2015年6月—2016年6月收治的喘息性小儿支气管炎患儿70例作为研究对象,将其随机分为观察组和对照组,每组各35例。对照组采用监测生命体征变化,给予抗感染、对症进行常规治疗,观察组患者在常规治疗的基础上增加孟鲁司特钠治疗,对比两组的治疗效果。结果观察组患者的临床治疗有效率为94.29%,高于对照组(80.00%),差异具有统计学意义(P<0.05);观察组临床症状消失时间及平均住院时间少于对照组(P<0.05)。结论采用孟鲁司特钠可以有效的治疗喘息性小儿支气管炎,有效改善患者的气道高反应性状态,进一步提高治疗效果。Objective To analyze the child bronchitis （asthmatic） by montelukast sodium in the treatment of clinical observation and preventive effect on airway hyperresponsiveness body. Methods 70 children with wheezing bronchitis in our hospital from June 2015 to June 2016 were selected as the study objects, which were randomly divided into observation group and control group, 35 cases in each group. The control group was used to monitor the changes in vital signs, anti infection and symptomatic treatment, the observation group was treated with montelukast on the basis of routine treatment, and the therapeutic effects of the two groups were compared. Results The effective rate of clinical treatment in the observation group was 94.29%, higher than that in the control group （80.00%）, and the difference was statistically significant （P 〈 0.05）. The disappearance time of clinical symptoms and the average length of stay in observation group were less than that in control group （P〈0.05）. Conclusion Montelukast can effectively treat asthmatic bronchitis, improve the airway hyperresponsiveness, and further improve the treatment effect.

关 键 词：喘息性支气管炎 孟鲁司特钠 临床疗效 气道高反应性 

分 类 号：R562.21[医药卫生—呼吸系统]